Back to search

Netherlands· NL-58be69802b3b

PROTAGENS 2%, oogdruppels oplossing

A künstliche tränenflüssigkeit und sonstige indifferente präparate product containing povidon k 25 (e 1201), registered in Netherlands by Alcon Nederland B.V.. The same ATC class is registered in 11 of our 19 countries.

ATC S01XA20

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedPROTAGENS 2%, oogdruppels oplossingATCS01XA20REGISTER NO.NL-58be69802b3bPACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Künstliche tränenflüssigkeit und sonstige indifferente präparate is registered in 11 of 19 countries.

Countries holding a registration under ATC S01XA20 (künstliche tränenflüssigkeit und sonstige indifferente präparate), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose

Künstliche tränenflüssigkeit und sonstige indifferente präparate · ATC S01XA20

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
POVIDON K 25 (E 1201)
Manufacturer
Alcon Nederland B.V.
Country
Netherlands (NL)
ATC code
S01XA20
ATC class
Künstliche Tränenflüssigkeit und sonstige indifferente Präparate
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    10513

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Künstliche tränenflüssigkeit und sonstige indifferente präparate in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All künstliche tränenflüssigkeit und sonstige indifferente präparate products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Belgium · Oculotect Unidose
  • France · Dulcilarmes, Fluidabak
  • Norway · Oculac

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b672b221-efa4-4de2-b7ce-d6957ccbd24d
GET /v1/drugs/b672b221-efa4-4de2-b7ce-d6957ccbd24d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oogdruppels, oplossing",
  "route": "Oculair gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h10513_smpc.pdf",
  "strength": null,
  "atc_label": "Artificial Tears And Other Indifferent Preparations",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg10513",
  "excipients": [
    "BENZALKONIUMCHLORIDE",
    "BOORZUUR (E 284)",
    "NATRIUMCHLORIDE",
    "NATRIUMHYDROXIDE (E 524)",
    "WATER, GEZUIVERD"
  ],
  "substances": [
    "POVIDON K 25 (E 1201)"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h10513.pdf",
  "authorised_at": "1984/04/27",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "10513",
  "additional_monitoring": "N"
}

See everything about künstliche tränenflüssigkeit und sonstige indifferente präparate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.